tezacitabine Report issue

Small molecule Experimental
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now
Tezacitabine is a ribonucleotide reductase inhibitor. It is a synthetic purine nucleoside analogue with potential antineoplastic activity. It is used in synthetic DNA.   Wikipedia

Chemistry

  • SMILES: Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)/C2=C\F)c(=O)n1.O
  • InChIKey: XPYQFIISZQCINN-QVXDJYSKSA-N
  • Mol. Mass: 275.24
  • ALogP: -1.07
  • ChEMBL Molecules:
    tezacitabine  
    tezacitabine  
More Chemistry

Pharmacology

Alternative names

2'-deoxy-2'-(fluoromethylene)cytidine | anhydrous | cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2e)- | fmdc | mdl 101731 | mdl 101,731 | mdl-101731 | mdl-101,731 | tezacitabine

Organizations (2)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Adenocarcinoma (Phase 2)

Colorectal Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Hematologic Neoplasms (Phase 1)

Stomach Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue